Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Clinical oncology 2019-07, Vol.16 (7), p.399-400 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 400 |
|---|---|
| container_issue | 7 |
| container_start_page | 399 |
| container_title | Nature reviews. Clinical oncology |
| container_volume | 16 |
| creator | D’Abreo, Nina Adams, Sylvia |
| description | Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events. |
| doi_str_mv | 10.1038/s41571-019-0216-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2229235169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A590155750</galeid><sourcerecordid>A590155750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-65f531a7acce9f1ee68a7cc72ad9dbc4979f9f7b217151ad050b7da8b701174f3</originalsourceid><addsrcrecordid>eNp1kV1rFTEQhhdRbK3-AG9kQRBvUjPZZHPSm1KKH4WCNwrehWx2ck7qbnJMsoX-e3M4tbVSmYtkZp53yORtmtdAj4F2qw-Zg5BAKChCGfSEPWkOQQpFuFyxp3d3yQ-aFzlfUdr3XHbPm4MOqOhq_bD5cTHPS0BiN2h_bqMPpfVh4wdffAyti6mdsZhcTPG2LclvJyQB1zW9xnZIWFutNcFiOmmzcVhuWudTLqcvm2fOTBlf3Z5HzfdPH7-dfyGXXz9fnJ9dEsslLaQXTnRgpLEWlQPEfmWktZKZUY2D5Uoqp5wcGEgQYEYq6CBHsxokBZDcdUfN-_3cbYq_FsxFzz5bnCYTMC5ZM8YU6wT0qqJv_0Gv4pJCfV2lOO9rUHlPrc2E2gcXSzJ2N1SfCUVBCClopY4foWqMOHsbAzpf6w8E7_4SbNBMZZPjtOz-OT8EYQ_aFHNO6PQ2-dmkGw1U72zXe9t1tV3vbNesat7cbrYMM453ij8-V4DtgVxbYY3pfvX_T_0Nrke12A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2244646407</pqid></control><display><type>article</type><title>Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?</title><source>SpringerLink Journals - AutoHoldings</source><creator>D’Abreo, Nina ; Adams, Sylvia</creator><creatorcontrib>D’Abreo, Nina ; Adams, Sylvia</creatorcontrib><description>Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.</description><identifier>ISSN: 1759-4774</identifier><identifier>EISSN: 1759-4782</identifier><identifier>DOI: 10.1038/s41571-019-0216-2</identifier><identifier>PMID: 31053774</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67/1059/2325 ; 692/4028/67/1347 ; 692/700/565/2194 ; Breast cancer ; Comment ; Cytotoxicity ; Drug therapy ; Immune checkpoint inhibitors ; Immunotherapy ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Oncology ; Safety and security measures</subject><ispartof>Nature reviews. Clinical oncology, 2019-07, Vol.16 (7), p.399-400</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2019 Nature Publishing Group</rights><rights>Springer Nature Limited 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-65f531a7acce9f1ee68a7cc72ad9dbc4979f9f7b217151ad050b7da8b701174f3</citedby><cites>FETCH-LOGICAL-c470t-65f531a7acce9f1ee68a7cc72ad9dbc4979f9f7b217151ad050b7da8b701174f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41571-019-0216-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41571-019-0216-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31053774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D’Abreo, Nina</creatorcontrib><creatorcontrib>Adams, Sylvia</creatorcontrib><title>Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?</title><title>Nature reviews. Clinical oncology</title><addtitle>Nat Rev Clin Oncol</addtitle><addtitle>Nat Rev Clin Oncol</addtitle><description>Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.</description><subject>692/4028/67/1059/2325</subject><subject>692/4028/67/1347</subject><subject>692/700/565/2194</subject><subject>Breast cancer</subject><subject>Comment</subject><subject>Cytotoxicity</subject><subject>Drug therapy</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Safety and security measures</subject><issn>1759-4774</issn><issn>1759-4782</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kV1rFTEQhhdRbK3-AG9kQRBvUjPZZHPSm1KKH4WCNwrehWx2ck7qbnJMsoX-e3M4tbVSmYtkZp53yORtmtdAj4F2qw-Zg5BAKChCGfSEPWkOQQpFuFyxp3d3yQ-aFzlfUdr3XHbPm4MOqOhq_bD5cTHPS0BiN2h_bqMPpfVh4wdffAyti6mdsZhcTPG2LclvJyQB1zW9xnZIWFutNcFiOmmzcVhuWudTLqcvm2fOTBlf3Z5HzfdPH7-dfyGXXz9fnJ9dEsslLaQXTnRgpLEWlQPEfmWktZKZUY2D5Uoqp5wcGEgQYEYq6CBHsxokBZDcdUfN-_3cbYq_FsxFzz5bnCYTMC5ZM8YU6wT0qqJv_0Gv4pJCfV2lOO9rUHlPrc2E2gcXSzJ2N1SfCUVBCClopY4foWqMOHsbAzpf6w8E7_4SbNBMZZPjtOz-OT8EYQ_aFHNO6PQ2-dmkGw1U72zXe9t1tV3vbNesat7cbrYMM453ij8-V4DtgVxbYY3pfvX_T_0Nrke12A</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>D’Abreo, Nina</creator><creator>Adams, Sylvia</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190701</creationdate><title>Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?</title><author>D’Abreo, Nina ; Adams, Sylvia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-65f531a7acce9f1ee68a7cc72ad9dbc4979f9f7b217151ad050b7da8b701174f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>692/4028/67/1059/2325</topic><topic>692/4028/67/1347</topic><topic>692/700/565/2194</topic><topic>Breast cancer</topic><topic>Comment</topic><topic>Cytotoxicity</topic><topic>Drug therapy</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Safety and security measures</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D’Abreo, Nina</creatorcontrib><creatorcontrib>Adams, Sylvia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D’Abreo, Nina</au><au>Adams, Sylvia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?</atitle><jtitle>Nature reviews. Clinical oncology</jtitle><stitle>Nat Rev Clin Oncol</stitle><addtitle>Nat Rev Clin Oncol</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>16</volume><issue>7</issue><spage>399</spage><epage>400</epage><pages>399-400</pages><issn>1759-4774</issn><eissn>1759-4782</eissn><abstract>Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31053774</pmid><doi>10.1038/s41571-019-0216-2</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-4774 |
| ispartof | Nature reviews. Clinical oncology, 2019-07, Vol.16 (7), p.399-400 |
| issn | 1759-4774 1759-4782 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2229235169 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | 692/4028/67/1059/2325 692/4028/67/1347 692/700/565/2194 Breast cancer Comment Cytotoxicity Drug therapy Immune checkpoint inhibitors Immunotherapy Medicine Medicine & Public Health Metastases Metastasis Oncology Safety and security measures |
| title | Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A40%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune-checkpoint%20inhibition%20for%20metastatic%20triple-negative%20breast%20cancer:%20safety%20first?&rft.jtitle=Nature%20reviews.%20Clinical%20oncology&rft.au=D%E2%80%99Abreo,%20Nina&rft.date=2019-07-01&rft.volume=16&rft.issue=7&rft.spage=399&rft.epage=400&rft.pages=399-400&rft.issn=1759-4774&rft.eissn=1759-4782&rft_id=info:doi/10.1038/s41571-019-0216-2&rft_dat=%3Cgale_proqu%3EA590155750%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2244646407&rft_id=info:pmid/31053774&rft_galeid=A590155750&rfr_iscdi=true |